Navigation Links
Duke to co-lead NIH research network on antibacterial resistance
Date:6/3/2013

DURHAM, N.C. -- Investigators at Duke Medicine and the University of California, San Francisco (UCSF) have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus (MRSA) and E. coli.

The research team will direct the allocation of a federal grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Duke has been awarded $2 million in initial funding to launch the network; total funding for the award will reach at least $62 million through 2019.

The grant creates a network of researchers who will design, prioritize, implement and manage a clinical research agenda to address antibacterial resistance, an issue that has been identified as one of the leading threats to human health worldwide. The group's goal is to develop new approaches that can benefit patients.

"Antibacterial resistance is an incredibly complex problem because of a convergence of issues: a dwindling pipeline of new products to treat infections, and a growing threat of antibiotic-resistant bacteria," said Vance Fowler, Jr., M.D., MHS, professor of medicine at Duke and one of the network's two principal investigators.

Antibiotics have been used for the past 70 years, significantly reducing illness and death from bacterial infections. However, some bacteria have adapted to the antibiotics designed to kill them, leaving the drugs less effective.

"Infections caused by drug-resistant bacteria are challenging to treat because one often has to rely on second- or third-line antibiotics, the effectiveness of which is not well known, or if known, is less than drugs of choice. These antibiotics may be more toxic, as well," said co-principal investigator Henry "Chip" Chambers, M.D., professor of medicine at UCSF and chief of the Division of Infectious Diseases at San Francisco General Hospital and Trauma Center.

To address this growing issue, NIAID created the Antibacterial Resistance Leadership Group. Led by researchers at the Duke Clinical Research Institute (DCRI) in collaboration with UCSF, the group serves as a central hub to identify, prioritize, execute and disseminate clinical research on antibacterial resistance. The global scientific community will be invited to submit proposals for research projects on antibacterial resistance, which the Antibacterial Resistance Leadership Group will review and fund based on alignment with the group's priorities.

"One of the strengths that we've tried to leverage in this project is the formidable expertise of a number of investigators across the United States," Fowler said. "We want to partner with these smart, talented, and driven investigators in the key areas we've identified."

The research effort will focus on four priorities:

  • Gram-negative bacteria, such as E. coli;
  • Gram-positive bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA;
  • Stewardship and infection control, which will determine how to best prevent infections, prescribe antibiotics and avoid overuse;
  • Devices and diagnostics, which will aim to reduce the amount of time it takes to determine what type of bacteria are causing infection.

"Gram-negative bacteria are front-and-center in our research agenda because the need for new treatments is greatest with them," Fowler said. He also stressed the importance of improving diagnostics, noting that technology will likely play a role in helping identify pathogens more quickly.

"For most bacterial infections, our diagnostic strategies are still fundamentally the same as they were 100 years ago," Fowler said. "We're still isolating, culturing and identifying bacteria that have been grown from a clinical sample. Each of those steps takes time, and clinicians don't always have the luxury of time.

"Reducing the time to knowledge would have the dual benefit of improving care for individual patients, but on a broader scale can serve to reduce the need for unnecessary antibiotics," Fowler said.

In addition to the four research priorities, the Antibacterial Resistance Leadership Group will focus attention on pharmacokinetics, or how drugs behave in patients, and antibacterial resistance in children.

The group will also work to cultivate the next generation of experts in antibacterial resistance by placing an emphasis on mentoring and training.

The group represents a partnership between NIAID staff and the antibacterial resistance research community, and will have the capacity to rapidly respond to emerging priority clinical research questions in antibacterial resistance.

The Antibacterial Resistance Leadership Group builds on a model of successful research networks led by Duke, including the Pediatric Trials Network and the NIAID-funded Center for HIV/AIDS Vaccine Immunology.

The structure of the DCRI also gives investigators the ability to perform complex clinical trials necessary for antibacterial resistance research.

"The track record that DCRI brings to the table for networks, particularly NIH-funded networks, is unprecedented," Fowler said.


'/>"/>

Contact: Rachel Harrison
919-419-5069
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Sofia University Professor Karen Erlichman to Co-Lead Spiritual Directors International Leadership Institute 2013
2. NIH to fund clinical research network on antibacterial resistance
3. Researchers identify genetic signature of deadly brain cancer
4. Dartmouth researchers test safety of Nivolumab in kidney cancer
5. North America Leads the Largest Market Share of the Bioinformatics Market Says New Research Report by MarketsandMarkets
6. New Hepatitis C Clinical Trial Now Enrolling at Avail Clinical Research near Orlando, Florida; Accepting M/F Patients with Hep C Age 18-65
7. Low Back Pain Clinical Trial Now Enrolling at Achieve Clinical Research in Birmingham, Alabama; Accepting M/F Patients with Chronic Low Back Pain Age 18-80
8. Monoclonal Antibodies Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research
9. Biscuit Production in China Industry Research Report – Now Available from IBISWorld
10. The Mesothelioma Applied Research Foundation Opened its 2013 Grant Cycle
11. Research Shows How Ritalin Affects Brains of Kids With ADHD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, ... and the Road To Recovery® program to drive cancer patients to and from their ... to ensure the highest quality of life and ongoing independence. Getting to and ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
(Date:6/23/2016)... Pa. , June 23, 2016 Bracket ... will launch its next generation clinical outcomes platform, Bracket eCOA ... Meeting held on June 26 – 30, 2016 in ... the first electronic Clinical Outcome Assessment product of its kind ... Booth #715. Bracket eCOA 6.0 is a flexible ...
Breaking Medicine Technology: